Program
Anti-CD7 CAR-T Cells RD13-02
Its studies are mostly in Diabetes Mellitus, Type 1, led by Nanjing Bioheng Biotech.
Furthest: early phase 1, since Aug 19, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Bioheng Biotech | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2025First study: early phase 1 study in Diabetes Mellitus, Type 1First studyNCT07142161 · 3 enrolled · China
TargetBeta
CD7 →read by rule
“A preparation of T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, ”NCIt, by rule
Other programs on CD7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Autologous Anti-CD7 CAR T Cells PA3-17rule | PersonGen BioTherapeutics (Suzhou) | phase 2 | 6 |
| UTAA07rule | PersonGen BioTherapeutics (Suzhou) | early phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07142161Diabetes Mellitus, Type 1 · China | Early 1 | Active, not recruiting | Jul 24, 2026 | 3 |
How it is read
Names in the registry
- “RD13-02 cell infusion”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.